Delivery of didanosine from enteric-coated, sustained-release bioadhesive formulation

Drug Delivery: Journal of Delivery and Targeting of Therapeutic Agents

Volumn 10, Issue 1, 2003, Pages 47-50

  Deshmukh, Deepali ^a   Ravis, William R ^a   Betageri, Guru V ^b  

^a AUBURN UNIVERSITY   (United States)

^b WESTERN UNIVERSITY OF HEALTH SCIENCES   (United States)

Author keywords

Didanosine (ddI); Enteric Coating; In vitro permeation; Stability; Tablets

Indexed keywords

2 PROPANOL; CHLORIDE; DICHLOROMETHANE; DIDANOSINE; HYDROXYPROPYLMETHYLCELLULOSE; POLYOX WSRN 303; SODIUM CHLORIDE;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DISSOLUTION; DOSE TIME EFFECT RELATION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG COATING; DRUG DELIVERY SYSTEM; DRUG RELEASE; DRUG STABILITY; DRUG STORAGE; IN VITRO STUDY; INTESTINE; MALE; MATHEMATICAL COMPUTING; NONHUMAN; PRIORITY JOURNAL; RAT; ROOM TEMPERATURE; SUSTAINED RELEASE FORMULATION; TEMPERATURE DEPENDENCE;

EID: 0037279273     PISSN: 10717544     EISSN: None     Source Type: Journal    
DOI: 10.1080/713840322     Document Type: Article

References (11)

1. Anderson, B. D., Wyangst, M. B., Xiang, T., Waugh, W. A., and Stella, V. J. 1988. Preformulation solubility and kinetic studies of 2′,3′-dideoxypurine nucleotides: Potential anti-AIDS agents. Int. J. Pharm. 45:25-25.
2. Betageri, G. V., Deshmukh, D., and Gupta, R. B. 2001. Oral sustained-release bioadhesive tablet formulation of Didanosine. Drug Dev. Ind. Pharm. 27:129-136.
3. Dolin, R., Lambert, J. S., Morse, G. D., Reichman, R. C., Plank, C. S., Reid, J., Knupp, C. A., McLaren, C., and Pettinelli, C. 1990. 2′,3′-dideoxyinosine in patients with AIDS or AIDS-related complex. Rev. Infect. Dis. 12:S540-S545.
4. Drusano, G. L., Yuen, G. J., Morse, G., Cooley, T. P., Seidlin, M., Lambert, J. S., Liebman, H. A., Valentine, F. T., and Dolin, R. 1990. Impact of bioavailability on determination of the maximal tolerated dose of 2′,3′-dideoxyinosive in phase I trial. Antimicrob. Agts. Chemother. 36:1280-1283.
5. Hartman, N. R., Yarchoan, R., Pluda, H. J. M., Thomas, R. V., Wyvill, K. M., and Flora, K. P. 1991. Pharmacokinetics of 2′-3′-dideoxyinosine in patients with severe human immunodefeciency virus infection. Clin. Pharmacol. Ther. 50:278-285.
6. Nassar, M. N., Chen, T., Relf, M. J., and Agharker, S. N. 1993. Didanosine. In Analytical Profiles of Drug Substances and Excipients, Vol. 22, ed. H. G. Brittain; pp. 187, Academic Press Inc. New York, NY.
7. Ravis, W. R., and Feldman, S. 1978. Effect of enzyme-inducing and enzyme-inhibiting agents on drug absorption I:3-O-methylglucose transport in rats. J. Pharm. Sci. 65:245-248.
8. Rozencweig, M., McLaren, C., Beltangady, M., Ritter, J., Canetta, R., Schacter, L., Kelly, S., Nicaise, C., Smaldone, L., Dunkle, R., Barbhaiya, C., Knupp, C., Cross, M., Tsianco, M., and Martin, R. R. 1990. Overview of phase I trials of 2′,3′-dideoxyinosine (ddI) conducted on adult patients. Rev. Infect. Dis. 12:S570-S585.
9. Shelton, M. J., O'Donnell, M. A., and Morse, G. D. 1992. Didanosine. Ann. Pharmacother. 26:660-670.
10. Sinko, P. J., Patel, N. R., and Hu, P. 1995. Site-specific oral absorption of didanosine: In situ characterization and correlation with the extent of absorption in vivo. Int. J. Pharm. 45:125-133.
11. Yarchoan, R., Mitsuya, H., Thomas, R. V., Pluda, J. M., Hartman, N. R., and Perno, C.-F. 1989. In vivo activity against HIV and favorable toxicity profile of 2′,3′-dideoxyinosine. Science 245:412-417.